MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412894 | Name: Ciladopa (free base)

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ciladopa (free base) is a dopamine agonist with a similar chemical structure to dopamine. It was under investigation as an antiparkinsonian agent but was discontinued due to concerns of tumorogenesis in rodents.

Chemical Structure

Ciladopa (free base)
Ciladopa (free base)
CAS#80109-27-9 (free base)

Theoretical Analysis

MedKoo Cat#: 412894

Name: Ciladopa (free base)

CAS#: 80109-27-9 (free base)

Chemical Formula: C21H26N2O4

Exact Mass: 370.1893

Molecular Weight: 370.45

Elemental Analysis: C, 68.09; H, 7.07; N, 7.56; O, 17.28

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
83529-09-3 (HCl) 80109-27-9 (free base)
Synonym
Ciladopa (free base); Ciladopum; UNII-D09L486R3J
IUPAC/Chemical Name
2,4,6-Cycloheptatrien-1-one, 2-(4-(2-(3,4-dimethoxyphenyl)-2-hydroxyethyl)-1-piperazinyl)-, (S)-
InChi Key
SGEKLKJQLHJVDK-LJQANCHMSA-N
InChi Code
InChI=1S/C21H26N2O4/c1-26-20-9-8-16(14-21(20)27-2)19(25)15-22-10-12-23(13-11-22)17-6-4-3-5-7-18(17)24/h3-9,14,19,25H,10-13,15H2,1-2H3/t19-/m1/s1
SMILES Code
O=C1C(N2CCN(C[C@H](C3=CC=C(OC)C(OC)=C3)O)CC2)=CC=CC=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 370.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Koller WC, Fields JZ, Gordon JH, Perlow MJ. Evaluation of ciladopa hydrochloride as a potential anti-Parkinson drug. Neuropharmacology. 1986 Sep;25(9):973-9. doi: 10.1016/0028-3908(86)90190-5. PMID: 3774130. 2: Lieberman A, Gopinathan G, Neophytides A, Pasternack P, Goldstein M. Advanced Parkinson's disease: use of partial dopamine agonist, ciladopa. Neurology. 1987 May;37(5):863-5. doi: 10.1212/wnl.37.5.863. PMID: 3574692. 3: Snider SR. More on ciladopa. Ann Neurol. 1987 Oct;22(4):558. doi: 10.1002/ana.410220426. PMID: 3435077. 4: Goodin DS, Aminoff MJ. PD and ciladopa. Neurology. 1988 Jan;38(1):167. doi: 10.1212/wnl.38.1.167. PMID: 3336454. 5: Aminoff MJ, Goodin DS, Habermann-Little B, Cutler JR. Treatment of Parkinson's disease with ciladopa. Ann Neurol. 1987 Mar;21(3):311. doi: 10.1002/ana.410210314. PMID: 3606037. 6: Weiner WJ, Factor SA, Sanchez-Ramos J, Berger J. A double-blind evaluation of ciladopa in Parkinson's disease. Mov Disord. 1987;2(3):211-7. doi: 10.1002/mds.870020308. PMID: 3332914. 7: Bagli J, Bogri T, Voith K, Lee D. Troponoids. 7. Chemistry and dopamine agonist activity of ciladopa and related aralkyltroponylpiperazines. J Med Chem. 1986 Feb;29(2):186-93. doi: 10.1021/jm00152a004. PMID: 3950903. 8: Koller WC, Herbster G. D1 and D2 dopamine receptor mechanisms in dopaminergic behaviors. Clin Neuropharmacol. 1988 Jun;11(3):221-31. doi: 10.1097/00002826-198806000-00004. PMID: 3261198. 9: Lang AE. Update on dopamine agonists in Parkinson's disease: "beyond bromocriptine". Can J Neurol Sci. 1987 Aug;14(3 Suppl):474-82. doi: 10.1017/s031716710003794x. PMID: 3315148. 10: Voith K. The comparative long-term effects of ciladopa (AY-27,110), a chemically novel dopaminergic agonist, in 6-OHDA-lesioned and intact rats. Psychopharmacology (Berl). 1985;85(4):405-9. doi: 10.1007/BF00429654. PMID: 3927334.